Worldwide Clinical Trials’ Post

In this webinar, learn how a novel immunoassay kit and multiplex platform streamlines biomarker screening, saving researchers time and preserving their precious samples. #AD Register today: https://ow.ly/qFJH50REU7o

In this webinar brought to you by Merck, learn how a novel immunoassay kit and multiplex platform streamlines biomarker screening, saving researchers time and preserving their precious samples. #AD Register today: https://ow.ly/Rs5F50RETs2

🚨New content alert! Check out Volume 2 of our ‘Metabolomics for Biomarker Discovery Application Book!’ https://mtbln.co/c9ux70 💡 The pursuit and discovery of #biomarkers is an incredibly important, pioneering area of life science research. Biomarkers are helpful in understanding the risks of developing diseases and predicting or monitoring the efficacy of drug therapies. 📘 In this collection of case studies, you will find five examples of how Metabolon has supported #biomarkerdiscovery with #metabolomics across various application areas, from inflammation research to renal failure. These stories illustrate the significant impact that metabolomics can have on biomarker discovery and how it can be used to overcome some of the challenges researchers face in identifying biomarkers. Download Now: https://mtbln.co/c9ux70 #metabolon #lifescienceresearch

Great discussions during the presentations at the Complement-based drug development summit. Dr. Michael Schwenkert shares insights on performing robust quantitative evaluation of biomarkers, functional detection of anaphylatoxins, and functional assessment of individual pathways- and convertase activity. #ComplementSummit #Complementbiology #ComplementingLifeScience #ComplementTherapeutics 

Streamline your screening projects. Listen to this on-demand webinar with The Scientist to hear from our and Luminex’s expert scientists and learn how combining the new MILLIPLEX® PLEXpedition screening assays with the xMAP® INTELLIFLEX® system can streamline your protein #biomarker screening. Watch now to see how easy it is to measure up to 115 biomarkers at once.

Unbiased evaluation of the global state of the complement system in various disease contexts has become essential, paving the way for targeted therapeutics, personalized treatment strategies, and improved patient outcomes. Discover our Svar Complement Biomarkers assays, trusted by the scientific community to assess and establish complement biomarkers across diverse diseases. Explore the possibilities: https://hubs.ly/Q02pXgbC0 Key Features: ✔️ Guided by specific neoepitopes: Ensuring precision and accuracy in the complexity of the complement system. ✔️ Speed and Precision: With ready-to-use reagents and short incubation times, get reliable and objective results in as little as 2 hours. ✔️ Objective Result Interpretation: The ELISA format allows for automatization, further reducing variability and ensuring a standardized and objective analytical approach. Remove uncertainty, reduce time, and secure specificity! #ComplementSystem #Biomarkers #ComplementingLifeScience #AnswersinLifeScience #ComplementBiology

🔬 Exciting news for biomarker and companion diagnostics enthusiasts - Here is the 2nd Annual MarketsandMarkets Biomarker and Companion Diagnostics Conference - East Coast Edition! 📅 Mark your calendars for June 20 - 21, 2024, in Boston, Massachusetts, USA. Register Now: https://bit.ly/3vt6ccB 🏙️ Organized by MarketsandMarkets Conferences, this in-person event offers insights into turning biomarkers into companion diagnostics. 🧬 #Biomarkers #BostonConference #eMedEvents

Streamline your screening projects. Listen to this on-demand webinar with The Scientist to hear from our and Luminex’s expert scientists and learn how combining the new MILLIPLEX® PLEXpedition screening assays with the xMAP® INTELLIFLEX® system can streamline your protein #biomarker screening. Watch now to see how easy it is to measure up to 115 biomarkers at once.

Searching for groundbreaking drug discovery methods? Move into iPSC technology. Disease models that express relevant biomarkers for your target disease will help you identify the best drug candidates earlier. Our human in vitro models are built to express the most relevant biomarkers and to closely mimic human pathophysiology, revolutionizing early-stage drug development. From research labs to clinical trials, having the right biomarkers in your models holds the key to invaluable insights. Explore our expertise in leveraging crucial information through human iPSC-derived disease models. Learn more: https://lnkd.in/ewWgFYWA #BiomarkerDetection #EfficacyScreening #drugdevelopment

A great opportunity to see firsthand how Omni automation has helped the group at Pfizer. If you are in town for WRIB conference, definitely check out this talk!